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Though  the  presence  of protein  antigens  in  pneumococcus  has  long  been 
recognized,  type specificity within  this  species has been  defined by capsular 
carbohydrates.  Much of the work on protein antigens of pneumococcus has 
dealt with a nucleoprotein fraction described by Avery and his  coworkers (1), 
and  there is general agreement that  this material exhibits species specificity. 
In quantitative studies of p neumococcus R-anti-R systems, however, Heidel- 
berger and Kabat (2) obtained results indicating the existence of a minor type- 
specific protein antigen in a  rough variant of pneumococcus type II (D39R), 
and later Heidelberger (3) suggested that the results permitted envisaging the 
possible existence,  in non-encapsulated pneumococci, of an antigen  that pos- 
sesses type specificity. 
In the hemolytic streptococci of Lancefield group A, in contradistinction to 
pneumococcus,  protein antigens play a  primary rSle in  the  determination  of 
type specificity (4).  Of these protein antigens,  the M  substance isolated by 
Lancefield, which belongs to the class of alcohol-soluble proteins, is of especial 
importance.  Proteins of this class have been found in several bacterial genera 
(5)  and their presence in pneumococcus has been noted heretofore  (6).  The 
present studies are concerned with  the properties and type specificity of such 
alcohol-soluble  M  proteins  of pneumococcus  and  with  the  demonstration  of 
their marked similarity to the M  proteins of group A streptococci. 
Materials  and  Methods 
Preparation of A nti-M Protein and Anti-C Carbohydrate Sera.--Sera were prepared accord- 
ing to the method employed by Goebel  and Adams (7) for the preparation of pneumococcus  C 
carbohydrate antisera.  Griffith  rough variants of the pneumococci studied were incubated 
overnight in neopeptone broth at 37°C., collected by centrifugation in the cold (4"C.), and 
resuspended in a volume of normal saline one-tenth that of the original culture.  The vaccine 
was heated then at 100°C. for 5 minutes.  Rabbits weighing  2 to 3 kilos were immunized daily 
for 6 days by intravenous injection of 1 cc. of the vaccine and were bled from the heart on the 
6th day following the final injection.  Two to four courses of immunization resulted usually in 
the production of satisfactory sera which possessed antibodies against the somatic C carbo. 
hydrate of pneumococcus  as well as against the type-specific  M protein.  An antipneumococ. 
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cus type XIX horse serum prepared by the New York City Department of Health and possess- 
ing a high titer of anti-C carbohydrate antibody was also employed. 
Preparation of M Protein E~razts.--Extracts of pneumococci were made according to the 
method of Swift, Wilson, and Lancefield (8).  To obtain a heavy growth of organisms for ex- 
traction, 1 per cent glucose was added to neopeptone broth cultures of pneumococci after in- 
cubation  overnight  and  the  acid  formed  on  subsequent  incubation  was  neutralized  in- 
termittently with 3 N NaOH.  The organisms were collected by centrifugation in the cold in 
an angle centrifuge prior to extraction.  To the packed cells,  sufficient N/5 HC1 was added to 
adjust the pH to 2.0-2.4.  The acid suspension was heated in a boiling water bath for 15 min- 
utes, cooled, centrifuged, and the supernatant decanted.  To the clear superuatant, a drop of 
0.01  per cent phenol red was added and  the solution was adjusted  to neutrality with N/2 
NaOH.  The cloudy solution was centrifuged again and the resultant clear supernatant was 
used for testing.  The extract thus obtained contains the M protein, the somatic or C carbo- 
hydrate, and if an encapsulated organism is employed, the capsular carbohydrate as well. 
Partial Purifwa~ion of M Protdn.--Two methods were employed to separate the M protein 
from C carbohydrate present in the cell extracts described.  The addition of 1 to 2 volumes 
of 95 per cent ethyl alcohol to the neutralized extract precipitated the M protein and left most 
of the somatic carbohydrate in solution.  This could be precipitated by the addition of 4 to 5 
volumes of alcohol.  The precipitates were collected by centrifugation and were readily sol- 
uble  in  normal  saline. 
The M  protein was purified partially also by the picrate method that Dodds and Dickens 
(9) employed for the purification of insulin.  To 2 volumes of cell extract was added 1 volume 
of saturated picric acid solution.  The precipitate was collected by centrifugation and  ex- 
tracted with 2 volumes of 70 per cent aqueous acetone.  To the acetone extract were added an 
equal volume of water and saturated picric acid.  The second precipitate was collected and 
treated with 1 to 2 volumes of acid alcohol (95 per cent C~I-IbOH, 3 volumes, 3 N HC1, 1 vol- 
ume).  The acid alcohol extract was added to 20 volumes of cold acetone from which the hy- 
drochloride of the M  protein precipitated in flocculent particles after several hours.  The 
precipitate was collected by centrifugation and was readily soluble in normal saline. 
Precipitin and Agglutination Tests.--Precipitin  tests were carried out either in small test 
tubes or in capillary tubes according to the method of Swift, Wilson, and  Lancefield (8). 
With the test tube technique, 0.3 co. of varying dilutions of cell extract was layered over 0.3 
co. of diluted serum containing 2 parts of serum and 3 parts of normal saline.  The tubes were 
incubated for 1 hour at 37°C. and the reactions read after standing overnight in the ice box. 
With the capillary method, undiluted serum was used and the reactions read after standing 
for 16 hours  at room temperature.  Agglutination tests were carried  out with a  constant 
amount of vaccine suspended in normal saline or in saline buffered with x~/50 phosphate buffer 
pH 7.2 and with serial dilutions of serum.  Tests were read after i hour's incubation at 37°C. 
and overnight incubation at 4°C. 
Strains of Pneumococc~.--In the work reported in this paper and in the following one (10), 
the naming of the colonial variants of pneumococcus employed is attended with certain diffi- 
culties.  Two nomenclatures for the colonial variants of pneumococcus are already extant. 
That of Griffith (11) includes only the encapsulated form designated by the letter S (smooth) 
and the more widely known of the unencapsulated forms designated by the letter R  (rough), 
selected by growing encapsulated  cells in antiserum directed against  the capsular polysac- 
charide.  This terminology has enjoyed general use in the description of pneumococcal strains. 
In 1934, Dawson (12) reported the existence of a second unencapsulated variant of pneumococ- 
cus, and to bring the nomenclature of pneumococcal colonial forms into conformity with that 
of other bacterial species, he suggested that encapsulated forms be designated by the letter M 
(mucoid), the previously described unencapsulated  form by the letter S  (smooth), and the 
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ial morphology and autoagglutinable properties.  There have been few reports concerning all 
three colonial variants of pneumococcus and the terminology of Dawson has not been used 
widely.  It is unfortunate that the nomenclatures of Grifl~th and of Dawson employ the same 
symbols to designate different colonial forms, for inevitable confusion is created thereby.  In 
the strains to be reported, variants designated smooth by Grifl~th and mucoid by Dawson will 
be referred to as encapsulated forms.  The more generally recognized unencapsulated variant 
known  as  rough in  Grifl~th's  nomenclature and  smooth in  Dawson's  terminology, will be 
designated by the term Griflith rough, and the less widely studied unencapsulated variant de- 
scribed first by Dawson will be described by the term Dawson rough.  This terminology, while 
admittedly unsatisfactory,  should minimize ambiguity.  A  more satisfactory nomenclature 
awaits a better understanding of colonial variation.  Appended below is a list of the strains of 
pneumococci used in the present studies.  Encapsulated strains are grouped by capsular type 
and unencapsulated strains are described immediately after the parent strain. 
Capsular Type l 
I-SVI: an encapsulated strain carried for many years in the laboratory. 
I-SV1-P86: an encapsulated, sulfonamide-resistant strain derived from I-SV1 in 1938. 
1-192R: a Gri~th rough strain derived from I-SV1 and carried for many years in the labora- 
tory. 
1-192RD:  a Dawson rough strain derived from 1-192R in 1948. 
I-Rack: an encapsulated strain carried for several years in the laboratory. 
I-Moody: an encapsulated strain  carried  for  several  years in  the  laboratory. 
I-JHHA:  an encapsulated strain  recovered from a brain  abscess  in  Baltimore in 1948. 
LJHHAR:  a Griflith  rough variant derived from strain  I-JHHA. 
I-JI-II-IB:  an encapsulated strain  isolated  from a patient  with  lobar  pneumonia in Baltimore 
in 1948. 
Capsular Type II 
II-D39S: an encapsulated strain carried for many years in the laboratory. 
H-R36A,  II-R36T,  and  II-R36NC:  three  colonial variants of the  Grifllth rough  strain 
II-R36 derived from  II-D39S. 
ILR36ND:  a Dawson rough variant derived from ILR36NC in 1948. 
II-BW: an encapsulated strain isolated from a patient with lobar pneumonia  in New York 
in 1948. 
ILBWR: a Grit~th rough variant derived from strain II-BW. 
II-BG and II-BS: two encapsulated strains isolated from patients with lobar pneumonia in 
New York in 1948. 
ILRat: a strain isolated from a rat during an epizootic in Baltimore in 1947. 
II-RatR:  a Griflith rough variant derived from strain II-Rat. 
II-JHH: an encapsulated strain isolated from a patient with lobar pneumonia in Baltimore 
in 1948. 
Capsular Type IH 
III-A66 and III-SV3: encapsulated strains carried for many years in the laboratory. 
III-A66R2: a Grifllth rough variant of strain III-A66. 
III-L and HI-H: two encapsulated strains isolated from throat cultures in New York in 
1948. 
III-Rack: an intermediate encapsulated  strain carried for several years in the laboratory. 442  TYPE-SPECIFIC PROTEIN FRO~f PNEUMOCOCCUS 
Capsular Type VIII 
VIII-H:  an encapsulated strain carried for several  years in the laboratory. 
VIII-R13: a Griflfith  rough variant derived from  strain VIII-H. 
VIII-RIH: an encapsulated strain carried for several  years in the laboratory. 
VIII-Romano: an encapsulated strain isolated from a patient with lobar pneumonia in 
New York in 1948. 
VIII-Marino: an encapsulated strain isolated from  a patient with meningitis in New York 
in 1948. 
Capsular Types IV, V, VH, IX, XA, XIV, XVII, XIX, XXIVA 
All these strains are strains of encapsulated organisms carried in the laboratory for several 
years. 
EXPEI~  IACE.NTAL 
Type Specificity of lnti-M Protein Sera.--Sera were prepared by immunizing 
rabbits  by  the  method  described in  the  preceding  section  with  heat-killed 
vaccines of Griffith rough pneumococcal strains 1-192R,  I-JHHAR, II-R36T, 
II-BWR, III-A66R2, and VIII-R13 derived respectively from pneumococci of 
capsular types I, I, II, II, III,  and VIII.  These sera, when tested before ab- 
sorption  with  extracts  of  homologous  and  heterologous pneumococci,  gave 
heavy precipitates with the homologous extracts and also of varying but lesser 
amount  with  heterologous extracts.  By absorbing  the  sera  with  the  mass 
growth of one or more strains of heterologous Griffith rough organisms, it was 
possible to remove the anti-C carbohydrate and other species-specific antibodies 
and also cross-reacting anti-M protein antibodies.  In addition, to insure the 
absence of antibody against the capsular carbohydrate of the parent strain, the 
sera were absorbed with 0.1 volume of a  1:10,000 solution of capsular carbo- 
hydrate.  Such absorbed sera, when tested by either the capillary or test tube 
precipitin technique, reacted specifically with cell extracts of the homologous 
strain (Table I).  The type-specific designations of the M  proteins studied are 
recorded in  Arabic  numerals  below  the  names  of the  pneumococcal strains 
employed in making anti-M sera.  Subsequent reference to anti-M sera will be 
to sera absorbed with the strains listed in column 2 of Table I unless otherwise 
noted. 
Three additional facts of interest are recorded in Table I.  Although strains 
1-192R and I-JHHAR were both derived from organisms  of capsular  type I, 
they possess different M proteins.  A similar difference in antigenic composition 
is  manifested  by the  two  strains  II-R36T and  II-BWR  both  derived from 
organisms of capsular type II.  In addition, there is recorded a cross-reaction 
between the sera and extracts of strains I-JHHAR and II-BWR.  When the 
two sera are absorbed reciprocally, precipitating antibodies for both homologous 
and heterologous strains are removed.  It appears, therefore, that organisms of 
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organisms of different capsular type may possess the same or closely similar 
proteins.  There is shown also in Table I the absence of serological relationship 
between the M proteins of pneumococci of capsular types III and VIII.  This 
finding is of interest in view of the known immunological relationship of the 
capsular polysaccharides  of these two types. 
TABLE  I 




1-192R  ILI-A66R2 
Type 1M  VIII-R13 
I-JHHAR  1-192R 
Type 2M  II-R36A 
VIII-R13 
II-R36T  1-192R 
Type 2'M  HI-A66R2 
VIII-R13 
II-BWR  II-R36T 
Type 2M  III-A66R2 
VIII-R13 
IILA66R2  1-192R 
Type 3M  II-R36A 
VIII-RI3  1-192R 
Type 8M 
Antiserum 
absorbed with  ~, 
strains  1-192R 
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In Table II are shown the reactions  of the sera listed above with extracts 
of 34 pneumococcal strains including 13 capsular types and their derivatives. 
All the strains of capsular  types III and VIII examined  reacted specifically 
with antisera prepared against a Griffith rough variant derived from the labora- 
tory strain of the homologous capsular type.  Strains of capsular type I and 
H, on the other hand, showed heterogeneity of their M  protein component. 
Two different proteins were found associated with each of these capsular types 
and in addition, strains of both types I and II were encountered that failed to 
react with antisera against any of these proteins. 
Relation of M  Protein to Colonial Variation.--The relation of M protein to 
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was present in the cells of both encapsulated and Griffith rough colonial vari- 
ants.  Its presence in quantity in the latter colonial form distinguishes it from 
the M protein of group A ¢~-hemolytic  streptococci, for little or no type-specific 
protein is found in the glossy variant of streptococcus  which has been  con- 
sidered  to be the colonial analogue  of the Griffith rough pneumococcus  (13). 
Further  degraded  rough  colonial  variants  of  pneumococcal  strains  1-192R 
and II-R36NC, obtained by the method of Dawson, were studied also for the 
presence  of M  protein.  Although the component could not be detected oc- 
casionally in Dawson rough variants derived from pneumococcus 1-192R, con- 
sistently deficient cultures were not obtained. 
Capillary Precipitin  Reaction 
Antiserum 
(absorbed as in Table I) 
1-192R (Typ¢ IM) 
I-JHHAR (Type 2M) 
II-Ra6T (Type  2'M) 
II-BWR (Type 2M) 
III-A55R2 (Type 3M) 
VIII-R13 (Type 8M) 
V++  +~  +++ 
++++  ÷+++ ++++  ++++ 
++- 
Species Specificity  of Pneumococcus C  Carbohydrate.--In  all  the  pneumo- 
coccal strains tested, regardless  of colonial morphology,  the presence  of the 
species-specific  C  carbohydrate could be  demonstrated.  For  this  purpose, 
the  use  of the Lancefield  extract fraction precipitated by concentrations of 
alcohol between  70 per cent and 83 per cent and redissolved  in normal saline 
proved most suitable (Table III).  Although solutions prepared in this manner 
reacted occasionally  with C-absorbed  anti-C rabbit sera,  the reactions  were 
always less intense than with unabsorbed sera.  No cross-reactions  of pneu- 
mococcus C carbohydrate were noted with sera containing antibodies  against 
the C carbohydrates of/J-hemolytic streptococci  of Lancefield's groups A, B, 
C, D, E, F, G, H, and L; nor were reactions  noted between pneumococcus C 
carbohydrate antisera and extracts of Streptococcus  MG, Streptococcus  salivarius, 
and a  strain of Streptococcus mitis.  Antisera prepared in either the horse or 
the rabbit can be used to test for the presence of C carbohydrate and the test 
appears to be a useful aid in the recognition of unencapsulated pneumococci. 
Chemical Properties o/ Pneumococcus M  Protein.--That  the  type-specific 
substance present in unencapsulated as well as in encapsulated pneumococci is a 
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(14) is revealed by the following data.  The M  protein can be extracted from 
pneumococcal cells by hot  acid  solutions  in which  it remains soluble.  It is 
soluble in acid ethyl alcohol but is precipitated by ethyl alchol from neutral 
solutions.  The serological reactivity of the material is destroyed by proteolytic 
enzymes as revealed in the following experiment:-- 
To 12.5 cc. of an extract of pneumococcus  I-SV1 was added 12.5 cc. of 95 per cent ethyl al- 
cohol.  The precipitate was collected by centrifugation, redissolved in 6 cc. of acid saline, and 
the pH adjusted to 1.95.  To two 2 cc. aliquots of the solution were added respectively 2 cc. 
of active and of heat-inactivated  2 per cent solutions of commercial crude pepsin, pH 2.5. 
After incubation for 2 hours at 37°C., the solutions were neutralized with 1 N NaOH and 
l M Extracts and Anti-M Scra 
~xtract type 
I: I++-÷+1  +-++ [ +-++ I +-++ / +-++ I-- t: 1  +-+ +;+ I+;+ I+;+ 
--  m 
cleared by centrifugation.  Serological reactions of the materials treated  in these ways are 
shown in Table IV. 
The  serological activity of the  type-specific substance is lost almost com- 
pletely after 2 hours' exposure to an active solution of pepsin.  Similar results 
are obtained with the use of commercial crude trypsin. 
Like the  M  proteins of group A  streptococci,  the  type-specific proteins of 
pneumococci form acetone-soluble picrates.  When  the  procedure of picrate 
precipitation  outlined  in a  preceding section is carried out,  partiaUy purified 
preparations  of M  protein  of high serological activity can be obtained from 
extracts of encapsulated or of Griflith rough variants.  One such preparation, 
when  examined  with  the  ultraviolet  spectrophotometer,  contained  approxi- 
mately 98 per cent protein, 2 per cent nucleic acid.  Whether or not pneumo- 
coccus M  protein is antigenic when treated by these methods has not yet been 
determined. 
Agglutinating  Properties  of zPneumococcus  M  Protein Antisera.--M  protein 
antisera  which  have been absorbed with  heterologous  Grifllth  rough  strains 
show selective agglutination of Griflith rough variants of the homologous strain 
(Table  V).  When  such  a  serum is  absorbed further with  a  solution  of ho- 446  TYPE-SPECIFIC PROTEIN FROM  PNEUMOCOCCUS 
TABLE  III 
Precipitin Reactions of Ethanol-Precipitated Fractions of Lancefield Extracts of Pneumococci with 
Pneumococous Anti-C Carbohydrate Rabbit Antiserum  before and after Absorption with C 
Carbohydrate 












1:2  ++]++  +  ++ +++ 
1:2o  +!  +  *  ++ 
+  ++ 
++ +++ ++++ +++  +++ 
4-  ,  ++  + 
I  i 
!  -  ÷  - 
1  -- 
I 
+++ ++ ~++ ++ ++ 
+  ++ ++  -*-  + 
++++ 
+++ 
* Pneumococcus C carbohydrate solution 1:25,000 diluted 1:2 and 1:20.  Extract  fraction precipitated by concen- 
trations of alcohol between 70 and 83 per cent.  Precipitin reactions performed with test tube technique. 
TABLE  IV 
Effect of Pepsin on M Protein of Pneumocoecus 
M Precipitin Reactions 
Extract I-SVI  Type I M rabbit antiserum 
Untreated extract  ++++ 
Pepsin-treated extract 
Inactive pepsin-treated extract  +++4_ 
Saline control 
Precipitin reactions performed with test tube technique. 
TABLE  V 









i 1:40  1:80  1:160  1:320  1:640  1:1280  1:2560  1:5120 
++  ++++  ++++  ++++  ++++  ++++  ++++  +++ 
++  +  ...... 
++  +  +  ..... 
* Antiserum prepared  against  strain  1-192R  and  absorbed  with  strains  ILR36A  and 
IILA66R2. 
mologous M  protein purified partially by the picrate method so that it gives no 
longer a  positive precipitin reaction,  it agglutinates  the homologous strain less 
well than previously but  to a  higher  titer  still  than  the  heterologous  strains. R.  AUSTRIAN  AND C. M.  MACLEOD  447 
Whether this finding indicates that the treatment of the M protein has altered 
it appreciably from its native state, the incomplete absorption of M  antibody 
or the presence of an additional type-specific agglutinin cannot be stated at 
this time.  M  protein antisera do not agglutinate encapsulated variants of the 
homologous strain nor do they give rise to a quellung reaction with homologous 
encapsulated or unencapsulated organisms. 
TABLE VI 
Loss of Agglutinability of Pneumococcus 1-1921{ by Homologous Anti-M Serum Following 
Exposure to Pepsin 
Vaccine used  in  agglutination  reaction 
Pepsin-treated  cells 
2 hrs.  at 37°C. 
Inactive pepsin-treated  cells 
2 hrs. at 37°C. 
Antiserum*  dilution 
+~++i ~~~~-~~~+~+~--~  --~---1~0  [ 1:80  1:160 1:320 1:640 1:12801:25501:51601:10,240 
Saline 
control 
*  See footnote  to Table V. 
TABLE VII 
Disappearance of M  Protein from Pneumococcal Cdls Following Exposure to Pepsin 
M  Precipitin Reactions with Cells ~  f Pneumoeoceus 1-192R 
Extract from:  Antiserum ~s:  pneumococcus 1-192R 
Pepsin-treated cells 
2 hrs. at 37°C. 
Inactive pepsin-treated cells 
2 hrs. at 37°C. 
++++ 
Capillary tube technique. 
Effect of Proteolytic Enzymes on the M  Protein of Intact Pneumococcal Cells.-- 
As is true of the M proteins of group A streptococci (15), those of pneumococcus 
are susceptible in the intact cell to the action of proteolytic enzymes.  When 
heat-killed pneumococcal cells are subjected to the action of commercial crude 
pepsin,  their  agglutinability  by  homologous  anti-M  serum  is  almost  com- 
pletely lost and no M protein can be demonstrated in extracts made from ceils 
so treated (Tables VI and VII).  The morphology of the ceils and their reac- 
tion to the Gram stain are unaltered by exposure to the enzyme under these 
conditions. 
Lack  of Protective  Effect  of Pneumococcal  M  Protein  Antisera.--M  protein 
antisera  appear  not  to  have an  important  effect upon  the  virulence of ho- 
mologous encapsulated pneumococci.  Mice inoculated intraperitoneally with 
1 cc. of anti-type 1 M  serum 24 hours before intraperitoneal injection with a 448  TYPE-SPECIFIC PROTEIN [FROM  PNEU~OCOCCUS 
10-7 dilution of a fully virulent culture of pneumococcus I-SV1 failed to survive 
longer than mice injected with normal rabbit serum or than untreated controls 
(Table VIII). 
Absence  of Cross-Reactions  among  Pneumococcal  and  Streptococcal  M  Pro- 
teins.--Because of the similar chemical properties of the type-specific M proteins 
of pneumococci and of group A streptococci, extracts of pneumococcus strains 
1-192R,  II-R36A, III-A66R2, and VIII-R13 were tested  with antisera against 
group A streptococci types 1, 3, 5, 6,  14, 17, 18, 19, 23, 24, 26, 28, 30, 31, 36, 
and 42 and absorbed sera against the same pneumococcus strains were  tested 
with extracts of group A/3-hemolytic streptococci types 1, 2, 3, 4, 5, 11, 12, 13, 
TABLE VIII 
Failure of Anti-M S~rum to Protect Mice Infecte,  d with Homologous Encapsulated Pneumococci 
Strain of  Amount of culture 










1 cc. type 1 M rabbit antiserum 







Serum injected intraperitoneally  24 hours before  inoculation  intraperitoneally  with pneu- 
mococcus culture.  Type 1 M antiserum prepared against strain 1-192R, absorbed with 
C carbohydrate. 
* D/S, ratio of dead to surviving mice. 
14, 15, 17, 19, 22, 23, 24, 26, 28, 29, 30, 31, 33, 36, 37, 41, 43, 44, and 46.  No 
cross-reactions were noted. 
DISCUSSION 
The present studies reveal the hitherto unrecognized type specificity of a 
protein antigen of pneumococcus.  This antigen is present in both encapsulated 
and unencapsulated colonial variants and unlike  the  analogous  type-specific 
protein of several groups of streptococci  (12),  it is found in most cultures of 
Dawson rough variants.  The M  proteins of pneumococcus are an important 
factor in determining the antigenic heterogeneity of unencapsulated members of 
this species.  All their chemical properties that have been studied so far appear 
similar to those of the M  proteins of group A streptococci.  The proteins of 
both species are soluble in hot 0.2 N acid, and in acid ethyl alcohol and the 
members of both groups form acetone-soluble picrates.  The M proteins of both 
species appear to be located at or near the surface of the cell because they are 
destroyed by the action of proteolytic enzymes which do not produce con- 
comitant morphological changes, and in both species they function as agglu- 
tinogens and precipitinogens.  Despite these many similarities, no cross-reac- R.  AUSTRIAN  AND  C.  M.  MAcLEOD  449 
tions have been noted yet between pneumococcal and streptococcal  M proteins 
but it does not seem unlikely that such may be found. 
Unlike the M proteins  of group A streptococci,  the M proteins  of pneumo- 
coccus appear to play a negligible r61e in the determination of pneumococcal 
virulence.  Evidence of this fact may be drawn from the inefficacy of anti-M 
serum  in  protecting  the  white  mouse  against  infection with  encapsulated 
pneumococci  of  the  homologous  type.  Further  evidence  of  this  negative 
correlation will be reported in the following paper (10). 
Examination of a number of strains of pneumococci of the same capsular 
type shows that the same capsular carbohydrate may be associated in different 
strains with dissimilar M  proteins.  This observation  suggests that the syn- 
thesis and functions of the capsular carbohydrate and M protein may be un- 
related.  It creates  also a  taxonomic  problem.  Because the same or closely 
similar  proteins seem to be present in organisms  of the same capsular  type 
isolated recently, it is suggested tentatively that the protein occurring in such 
organisms be given the Arabic number corresponding  to the Roman numeral 
designating the capsular type.  Proteins found subsequently to be associated 
with the same  capsular carbohydrate may be  designated by prime,  double 
prime,  or triple prime notations in the order of their identification.  The as- 
sociation of different M proteins with pneumococci of the same capsular type 
is a finding of potential interest in the study of pneumococcal disease, for this 
phenomenon may provide  a tool for the recognition of dissimilarity of organ- 
isms of the same capsular  type which manifest differences in epidemiological 
behavior. 
The presence  of the  M  protein  in pneumococcus  provides  an additional 
feature of similarity between members of this species and the streptococci.  In 
addition, it has been shown that the C carbohydrate of pneumococcus can be 
used for identification of this species in a manner similar to that employed in the 
classification of certain of the streptococci.  These observations  lend support 
to those who would classify pneumococcus in the genus Streptococcus  rather than 
under the separate generic name Diplococcus. 
SUMMARY 
The isolation  and characterization of a type-specific M protein from pneu- 
mococcus  are  described.  This protein  is  similar  chemically  in  all respects 
studied to the M proteins of group A streptococci.  No immunological cross- 
reactions have been observed, however, between M proteins of the two species. 
Strains of capsular type I pneumococcus have been encountered which con- 
tain different M proteins.  The same is true for capsular type II pneumococcus. 
It is apparent,  therefore,  that the capsular  polysaccharides  and M  proteins 
can vary independently  of each other. 450  TYPE-SPECIFIC PROTEIN ~FRO'~ PNEUMOCOCCUS 
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